TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Income from Continuing Operations came in at 103000.0 in Q1 2026, up 116.19% YoY from 47642.18 in Q1 2025, and up 117.76% on a QoQ basis from 580000.0 in Q4 2025.
TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 17 years of Income from Continuing Operations data on file, last reported at 103000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 116.19% year-over-year to 103000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 118000.0 (up 105.44% YoY) and the FY2025 annual result came in at 653000.0, up 71.76% from the prior year.
- Income from Continuing Operations rose to 103000.0 in Q1 2026, from 580000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 48453000.0 in Q4 2022 to a low of 17875000.0 in Q1 2022.
- A 5-year average of 575235.29 and a median of 809000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 151.9% in 2025, down 798.8% in 2025.
- Tracing TXMD's Income from Continuing Operations over 5 years: stood at 48453000.0 in 2022, then plunged by 103.27% to 1584000.0 in 2023, then surged by 105.24% to 83000.0 in 2024, then slumped by 798.8% to 580000.0 in 2025, then surged by 117.76% to 103000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 103000.0 (Q1 2026), 580000.0 (Q4 2025), and 50000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 164,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164,000.00 |
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 545,000.00 |
| Mar 31, 2025 | -636,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | -567,000.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -809,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | -1.43 Mn |
| Jun 30, 2023 | -2.41 Mn |
| Mar 31, 2023 | -2.31 Mn |
| Dec 31, 2022 | 48.45 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | -15.42 Mn |
| Mar 31, 2022 | -17.88 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |